#USA #New York #Novo Nordisk #Wegovy #Ro

Ro Enhances Access to Wegovy® Pill

Ro, a leading direct-to-patient healthcare company, has made a significant move in the obesity treatment market by collaborating with Novo Nordisk for the nationwide launch of the Wegovy® pill. This oral GLP-1 weight loss medication marks a pivotal moment for patients seeking effective obesity management solutions. Patients can now easily access Wegovy® through Ro's platform, benefiting from the lowest available cash pay prices.

The partnership began in April 2025, positioning Ro as a crucial player in the direct-to-patient strategy of Novo Nordisk. The Wegovy® pill is designed to offer those who have avoided medication therapies due to traditional administration methods a more convenient alternative.

According to statement made by Dave Moore, Executive Vice President, U.S. Operations for Novo Nordisk, the accessibility of the Wegovy® pill via Ro's platform ensures that clinically eligible patients can navigate their treatment journey seamlessly—from diagnosis to medication delivery—all through a single channel.

Ro's vertically integrated approach not just streamlines the healthcare experience but also guarantees that patients receive high-quality care throughout their treatment. Recently, Ro released the first peer-reviewed study that assessed the long-term weight loss and safety outcomes associated with semaglutide treatment via telehealth—the active ingredient in Wegovy®. This study revealed that participants successfully lost an average of 16.6% of body weight over a 68-week period, demonstrating the efficacy of the treatment through Ro's platform.

Zach Reitano, Ro’s co-founder and CEO, emphasized the significance of launching Wegovy® on Day 1 in collaboration with Novo Nordisk, pointing out that this innovative strategy can greatly enhance access to groundbreaking medications. He remarked that Ro’s direct-to-patient model helps yield clinical trial-like outcomes for patients at the lowest prices for FDA-approved treatments.

Ro’s obesity care formulary stands out as one of the most comprehensive in the telehealth space. It merges cash pay and insurance-qualifying options, providing medication delivery directly to patients' homes or the ability for pick-up at local pharmacies. Additionally, Ro's GLP-1 Insurance Checker allows individuals to verify their benefits coverage at no charge, ensuring that they can access their medications at the best possible prices, whether through insurance or direct payment.

To date, Ro has aided over 2 million patients in understanding their benefits coverage, ensuring that they can choose the most suitable treatment options for their needs. For more insights into Ro’s Body Membership and the holistic range of GLP-1 solutions, visit Ro.co/weightloss.

About Ro

Founded in 2017, Ro is a transformative direct-to-patient healthcare company committed to helping individuals reach their health goals. It achieves this through an integrated healthcare experience that encompasses everything from diagnosis to medication delivery and ongoing support. Ro has influenced millions of patients nationwide, ensuring access to care even in 99% of primary care deserts across the United States.